Physician profile
Dmitry Ostrovskiy
NPI 1730462326
$6,061.03
in general payments reported to CMS, 2019-2025
26 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,611 · 2022: $1,179 · 2023: $697 · 2024: $1,162 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.28 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,029.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $655.81 | 2022 | |
| Pfizer INC. | $512.11 | 2023-2024 | |
| Eisai INC. | $391.55 | 2024-2025 | |
| Valinor Pharma, LLC | $345.36 | 2024-2025 | Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.41 | 2021-2025 | Relistor |
| Vertex Pharmaceuticals Incorporated | $203.13 | 2024-2025 | |
| Medtronic, INC. | $168.95 | 2022 | |
| Forte Bio-Pharma LLC | $162.65 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $132.43 | 2025 | |
| Nevro Corp. | $131.91 | 2024 | Senza |
| Indivior INC. | $123.18 | 2022-2025 | Sublocade |
| Almatica Pharma LLC | $100.41 | 2021-2023 | Gralise |
| Horizon Therapeutics Plc | $99.13 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $71.94 | 2022-2023 | Seglentis |
| Lundbeck LLC | $71.67 | 2025 | Vyepti |
| Mallinckrodt Hospital Products INC. | $62.59 | 2024-2025 | Acthar |
| Lilly USA, LLC | $52.63 | 2021-2022 | |
| Biogen, INC. | $51.10 | 2025 | Vumerity |
| Saluda Medical Americas, INC. | $44.23 | 2024 | Evoke |
| Nalu Medical, INC. | $32.99 | 2023 | Nalu Neurostimulation System |
| Grt US Holding, INC. | $24.67 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.18 | 2021 | |
| Virtus Pharmaceuticals LLC | $18.94 | 2021 | |
| Heron Therapeutics, INC. | $17.78 | 2023 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Ostrovskiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.